Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: SB-480848 Clear all
Completed Phase 1 Interventional

A Study To Determine The Effect Of SB-480848 On Asthma

NCT00368576
View directory record Official record
Conditions
Atherosclerosis
Interventions
SB 480848, tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Cypress, California • Normal, Illinois • North Dartmouth, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Healthy Volunteer Pharmacokinetic Study of Single and Repeat Doses of SB-480848

NCT00743860
View directory record Official record
Conditions
Atherosclerosis
Interventions
darapladib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment

NCT01711723
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib 160 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart

NCT00411073
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 2 Interventional

SB-480848 In Subjects With Coronary Heart Disease

NCT00269048
View directory record Official record
Conditions
Atherosclerosis
Interventions
SB-480848, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
969 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
28
States / cities
Birmingham, Alabama • Northport, Alabama • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2016 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study With Darapladib to Collect Tolerability Information

NCT00704431
View directory record Official record
Conditions
Atherosclerosis
Interventions
SB-480848 (darapladib)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects

NCT01873339
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib, Midazolam
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).

NCT01852565
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib, Diltiazem
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects

NCT01154114
View directory record Official record
Conditions
Atherosclerosis
Interventions
darapladib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating the Concentrations of Darapladib in Blood and the Safety of This Compound in Healthy Japanese Men

NCT00551317
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib (SB480848)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
20 Years to 64 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Sep 2, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial

NCT01000727
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Darapladib 160 mg, Placebo, Standard Therapy
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
13,026 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
290
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 252 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Sep 2, 2026, 10:55 AM EDT